4.34
-0.02 (-0.46%)
| Previous Close | 4.36 |
| Open | 4.39 |
| Volume | 191,500 |
| Avg. Volume (3M) | 1,458,329 |
| Market Cap | 3,476,409,600 |
| Price / Sales | 8.53 |
| Price / Book | 1.17 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2024 |
| Profit Margin | -104.01% |
| Operating Margin (TTM) | -95.87% |
| Diluted EPS (TTM) | -0.540 |
| Quarterly Revenue Growth (YOY) | 61.60% |
| Total Debt/Equity (MRQ) | 0.55% |
| Current Ratio (MRQ) | 5.35 |
| Operating Cash Flow (TTM) | -174.69 M |
| Levered Free Cash Flow (TTM) | -420.12 M |
| Return on Assets (TTM) | -7.01% |
| Return on Equity (TTM) | -11.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | OCUMENSION-B | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 0.25 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| OCUMENSION-B | 3 B | - | - | 1.17 |
| GENSCRIPT BIO | 23 B | - | - | 2.42 |
| HBM HOLDINGS-B | 3 B | - | 17.00 | 2.77 |
| TOT BIOPHARM-B | 1 B | - | 190.00 | 1.70 |
| AKESO | 55 B | - | - | 9.50 |
| INNOVENT BIO | 53 B | - | - | 4.54 |
|
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 52.83% |
| % Held by Institutions | 21.99% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |